F
Ford Motor Company
F lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
MRM
MEDIROM Healthcare Technologies Inc.
There isn't enough reported data to score MRM yet.
F Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
F's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
MRM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| Unavailable | |
| Unavailable |
There isn't enough reported data to rate MRM's fundamentals.
F PE Valuation
F has no meaningful PE right now: it lost money over the past year.
MRM PE Valuation
MRM has no meaningful PE right now: it lost money over the past year.
F Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect F's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
MRM Forward outlook
There aren't enough analyst estimates for MRM to show an outlook.
F Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.78 | — |
| Q3 2026 | -$1.97 | -270% |
| Q2 2026 | -$1.87 | -340% |
| Q1 2026 | -$1.55 | -224% |
| Q4 2025 | -$2.06 | -241% |
| Q3 2025 | $1.16 | +32% |
| Q2 2025 | $0.78 | -19% |
| Q1 2025 | $1.25 | +29% |
| Q4 2024 | $1.46 | +35% |
F has swung to a loss: it lost $1.97 per share over the past year, after a profit the year before.
MRM Earnings Per Share
MRM and F do not have enough comparable growth data to identify a winner.
F Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $49.5B | -2% |
| Q2 2026 | $48.3B | -3.8% |
| Q1 2026 | $43.3B | +6.4% |
| Q4 2025 | $45.9B | -4.8% |
| Q3 2025 | $50.5B | +9.4% |
| Q2 2025 | $50.2B | +5% |
| Q1 2025 | $40.7B | -5% |
| Q4 2024 | $48.2B | +4.9% |
F has the edge over MRM in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.9% | -0.1 points |
| Q2 2026 | 1.3% | +0.3 points |
| Q1 2026 | 5.4% | +4.6 points |
| Q4 2025 | -25% | -28 points |
| Q3 2025 | 3.1% | +1.2 points |
| Q2 2025 | 1% | -2.9 points |
| Q1 2025 | 0.8% | -2.1 points |
| Q4 2024 | 2.5% | +3.1 points |
F's operating margin was 2.9% last quarter, about level with the same quarter a year ago.
MRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $3.8M | -87% |
| Q2 2025 | $20.3M | -6.7% |
| Q4 2024 | $30.2M | +35% |
| Q2 2024 | $21.8M | +7.2% |
| Q4 2023 | $22.5M | -5.8% |
| Q2 2023 | $20.3M | +106% |
| Q4 2022 | $23.9M | +132% |
| Q2 2022 | $9.9M | -26% |
MRM's revenue has held roughly level: $4M last quarter, down 83% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 12% | +14 points |
| Q2 2025 | -28% | -19 points |
| Q4 2024 | 13% | +6.2 points |
| Q2 2024 | -18% | -13 points |
| Q4 2023 | -2.3% | +12 points |
| Q2 2023 | -9.6% | +15 points |
| Q4 2022 | 6.6% | +60 points |
| Q2 2022 | -4.9% | +59 points |
MRM's operating margin was 12% last quarter, up 14 points from the same quarter a year ago.
F Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.1B | -40% |
| Q2 2026 | $2B | -54% |
| Q1 2026 | -$1.1B | -157% |
| Q4 2025 | $1.1B | +108% |
| Q3 2025 | $5.3B | +50% |
| Q2 2025 | $4.2B | +24% |
| Q1 2025 | $1.9B | +$2.6B |
| Q4 2024 | $530M | +169% |
F still generates free cash flow, though less than at its 2020 peak: $5.1B over the past year.
MRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2025 | -$2.3M | +$2.7M |
| Q4 2024 | -$6.8M | -$6.2M |
| Q2 2024 | -$5M | -$865.8K |
| Q4 2023 | -$634.9K | +$2.4M |
| Q2 2023 | -$4.2M | -$3.2M |
| Q4 2022 | -$3M | -$2.2M |
| Q2 2022 | -$1M | +$197.1K |
| Q4 2021 | -$825K | -4728% |
MRM has burned cash in most quarters: −$15M over the past year, against −$9M the year before.
F Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.2% | +89M shares |
| 1 year | +0.7% | +28M shares |
| 3 years | +0.6% | +26M shares |
| 5 years | +1% | +40M shares |
| Available history | +1.8% | +72M shares |
F has the edge over MRM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $311M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $150M |
F spent $311M buying back its own shares over the past year, up 107% from the year before.
MRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +3K shares |
| 1 year | +45% | +2.5M shares |
| 3 years | +85% | +3.6M shares |
MRM has 8M diluted shares, up 45% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q2 2024 | — |
| Q4 2023 | — |
| Q2 2023 | — |
| Q4 2022 | — |
| Q2 2022 | — |
| Q4 2021 | — |
| Q2 2021 | — |
F Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.5x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -3.4x | Net Cash |
| Q3 2025 | -2.4x | Net Cash |
| Q2 2025 | -2.2x | Net Cash |
| Q1 2025 | -1.8x | Net Cash |
| Q4 2024 | -1.8x | Net Cash |
F has more cash than debt.
MRM Net Leverage
MRM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
F Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.5 | Neutral |
| Stochastic | 19.6 | Oversold |
F's weekly RSI is 41 (neutral) and its Stochastic is 20 (oversold).
MRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.1 | Oversold |
| Stochastic | 6.2 | Oversold |
MRM's weekly RSI is 22 (oversold) and its Stochastic is 6 (oversold).
F PE vs Consumer Cyclical Sector
| Metric | F | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
F has no meaningful PE right now: it lost money over the past year.
MRM PE vs Consumer Cyclical Sector
| Metric | MRM | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
MRM has no meaningful PE right now: it lost money over the past year.
F Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.2 | 2.5% below |
| 20 week MA | $13.3 | 11% below |
| 50 week MA | $13.4 | 11% below |
| 100 week MA | $12.1 | 2% below |
| 200 week MA | $12.1 | 1.4% below |
F is in a downtrend: it's below all five of its weekly moving averages, and 1.4% below its 200-week average.
MRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.43 | 35% below |
| 20 week MA | $0.74 | 62% below |
| 50 week MA | $1.15 | 76% below |
| 100 week MA | $1.28 | 78% below |
| 200 week MA | $3.21 | 91% below |
MRM is in a downtrend: it's below all five of its weekly moving averages, and 91% below its 200-week average.
F Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.36 | $8.86 | -5.3% |
| 2021 | $8.86 | $20.3 | +129% |
| 2022 | $20.3 | $11.4 | -44% |
| 2023 | $11.4 | $12.2 | +7.3% |
| 2024 | $12.2 | $10.0 | -18% |
| 2025 | $10.0 | $13.3 | +33% |
| 2026 YTD | $13.3 | $11.9 | -11% |
F has the edge over MRM on returns for 2026, with the stronger performance.
MRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $14.4 | $6.26 | -57% |
| 2022 | $6.26 | $5.58 | -11% |
| 2023 | $5.58 | $5.72 | +2.5% |
| 2024 | $5.72 | $1.05 | -82% |
| 2025 | $1.05 | $2.21 | +110% |
| 2026 YTD | $2.21 | $0.28 | -87% |
MRM's yearly returns have swung widely, from +110% in 2025 to −82% in 2024. It's down 87% so far in 2026.